Qube Research & Technologies Ltd Purchases 46,182 Shares of Health Catalyst, Inc. (NASDAQ:HCAT)
Qube Research & Technologies Ltd Purchases 46,182 Shares of Health Catalyst, Inc. (NASDAQ:HCAT)
Qube Research & Technologies Ltd grew its position in shares of Health Catalyst, Inc. (NASDAQ:HCAT – Get Rating) by 870.7% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 51,486 shares of the company's stock after acquiring an additional 46,182 shares during the quarter. Qube Research & Technologies Ltd owned about 0.10% of Health Catalyst worth $1,345,000 as of its most recent filing with the Securities & Exchange Commission.
根據Qube Research&Technologies Ltd.在提交給美國證券交易委員會的最新Form 13F文件中的數據,該公司在健康催化劑公司(納斯達克:HCAT-GET Rating)的股票中的頭寸在第一季度增加了870.7%。該機構投資者在本季度增持了46,182股後,持有51,486股該公司股票。截至最近提交給美國證券交易委員會的文件,Qube Research&Technologies Ltd擁有Health Catalyst約0.10%的股份,價值1,345,000美元。
Several other hedge funds and other institutional investors have also recently modified their holdings of HCAT. Rhumbline Advisers grew its holdings in Health Catalyst by 0.8% during the fourth quarter. Rhumbline Advisers now owns 49,095 shares of the company's stock worth $1,945,000 after buying an additional 409 shares in the last quarter. State Board of Administration of Florida Retirement System grew its holdings in Health Catalyst by 3.7% during the fourth quarter. State Board of Administration of Florida Retirement System now owns 14,024 shares of the company's stock worth $556,000 after buying an additional 499 shares in the last quarter. Envestnet Asset Management Inc. grew its holdings in Health Catalyst by 2.4% during the fourth quarter. Envestnet Asset Management Inc. now owns 22,519 shares of the company's stock worth $892,000 after buying an additional 525 shares in the last quarter. UMB Bank N A MO bought a new stake in Health Catalyst during the fourth quarter worth $30,000. Finally, Fairfield Bush & CO. bought a new stake in Health Catalyst during the first quarter worth $25,000. Institutional investors own 97.53% of the company's stock.
其他幾家對衝基金和其他機構投資者最近也調整了對HCAT的持股。Rhumbline Advisers在第四季度增持了Health Catalyst 0.8%的股份。Rhumbline Advisers在上個季度又購買了409股,現在擁有49,095股該公司股票,價值1,945,000美元。佛羅裏達州行政管理委員會的退休系統在第四季度增加了3.7%的Health Catalyst持有量。佛羅裏達州行政管理委員會退休系統現在擁有14,024股該公司的股票,價值556,000美元,在上個季度又購買了499股。Envestnet Asset Management Inc.在第四季度增持了Health Catalyst 2.4%的股份。Envestnet Asset Management Inc.現在持有22,519股該公司股票,價值892,000美元,該公司在上個季度又購買了525股。UMB Bank N A MO在第四季度購買了Health Catalyst價值3萬美元的新股份。最後,費爾菲爾德·布什公司。在第一季度購買了Health Catalyst價值2.5萬美元的新股份。機構投資者持有該公司97.53%的股票。
Analyst Ratings Changes
分析師評級發生變化
Several brokerages recently issued reports on HCAT. JPMorgan Chase & Co. downgraded Health Catalyst from an "overweight" rating to a "neutral" rating and decreased their price target for the stock from $20.00 to $16.00 in a report on Friday, August 5th. Piper Sandler cut their price target on Health Catalyst from $38.00 to $21.00 in a research note on Wednesday, May 11th. The Goldman Sachs Group lowered their price objective on Health Catalyst from $29.00 to $18.00 and set a "buy" rating on the stock in a research note on Wednesday, August 10th. Canaccord Genuity Group cut their target price on shares of Health Catalyst from $35.00 to $17.00 in a research report on Wednesday, May 11th. Finally, Royal Bank of Canada reduced their target price on shares of Health Catalyst from $35.00 to $19.00 in a research note on Wednesday, May 11th. Two research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $26.69.
幾家券商最近發佈了關於HCAT的報告。在8月5日星期五的一份報告中,摩根大通將Health Catalyst的評級從“增持”下調至“中性”,並將其股票目標價從20.00美元下調至16.00美元。派珀·桑德勒在5月11日星期三的一份研究報告中將其對Health Catalyst的目標價從38.00美元下調至21.00美元。8月10日,週三,高盛夫婦將Health Catalyst的目標價從29.00美元下調至18.00美元,並在一份研究報告中設定了該股的買入評級。在5月11日星期三的一份研究報告中,Canaccel Genuity Group將Health Catalyst的目標股價從35.00美元下調至17.00美元。最後,加拿大皇家銀行在5月11日星期三的一份研究報告中將Health Catalyst的目標價從35.00美元下調至19.00美元。兩名研究分析師對該股的評級為持有,9名分析師給予了買入評級,一名分析師對該股給予了強烈的買入評級。根據MarketBeat.com的數據,該公司目前的平均評級為“中等買入”,平均目標價為26.69美元。
Health Catalyst Price Performance
Health Catalyst性價比
Insider Buying and Selling at Health Catalyst
Health Catalyst的內部交易和銷售
In other news, General Counsel Daniel H. Orenstein sold 2,838 shares of the business's stock in a transaction that occurred on Monday, June 6th. The shares were sold at an average price of $14.85, for a total value of $42,144.30. Following the completion of the sale, the general counsel now directly owns 103,671 shares in the company, valued at approximately $1,539,514.35. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders sold a total of 4,395 shares of company stock worth $64,359 over the last three months. 1.50% of the stock is owned by insiders.
在其他新聞方面,總法律顧問Daniel·H·奧倫斯坦在6月6日星期一的一筆交易中出售了2,838股該公司的股票。這些股票的平均價格為14.85美元,總價值為42,144.30美元。出售完成後,總法律顧問現在直接擁有該公司103,671股,價值約1,539,514.35美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的,可以通過這個超級鏈接獲得。在過去的三個月裏,內部人士總共出售了4395股公司股票,價值64,359美元。該公司1.50%的股份由內部人士持有。
About Health Catalyst
關於Health Catalyst
(Get Rating)
(獲取評級)
Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations. Its offerings include data and analytics platform, a commercial-grade data and analytics platform for the healthcare sector; AI and data science, providing integration of AI into existing business intelligence tools, increasing analytics accuracy; population health management identifies improvement across the care continuum as well as actionable guidance for success and automated workflows; financial transformation providing costing and labor productivity insights and revenue capture; quality and safety improvement using clinical quality and patient safety data, analytics, and expert services; and national data ecosystem for thought leadership and mutual knowledge exchange to transform care delivery through next-gen insights.
Health Catalyst,Inc.為醫療保健組織提供數據和分析技術和服務。其產品包括數據和分析平臺,這是一個面向醫療保健部門的商業級數據和分析平臺;人工智能和數據科學,提供將人工智能集成到現有商業智能工具中,提高分析準確性;人口健康管理,確定整個醫療連續體系的改善,以及成功和自動化工作流的可行指導;金融轉型,提供成本計算和勞動生產率洞察和收入獲取;使用臨牀質量和患者安全數據、分析和專家服務來改進質量和安全;以及國家數據生態系統,用於思想領先和相互知識交流,以通過下一代洞察來轉變醫療交付。
Read More
閲讀更多內容
- Get a free copy of the StockNews.com research report on Health Catalyst (HCAT)
- 3 Blowout Earnings Reports That Could Mark Turning Points
- Will CrowdStrike Extend Its Streak Of Topping Earnings Views?
- 3 Stocks Set to Lead the Nasdaq Bull Market
- Skyworks Solutions Is Worth A Look At These Prices
- MarketBeat Podcast: ESG – Profitably Invest Your Values
- 免費獲取StockNews.com關於Health Catalyst(HCAT)的研究報告
- 3份井噴式收益報告可能標誌着轉折點
- CrowdStrike是否會延續其盈利排行榜榜首的勢頭?
- 3只股票將引領納斯達克牛市
- Skyworks Solutions值得看看這些價格
- MarketBeat播客:ESG--有利可圖地投資你的價值
Want to see what other hedge funds are holding HCAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Health Catalyst, Inc. (NASDAQ:HCAT – Get Rating).
想看看其他對衝基金持有HCAT的情況嗎?訪問HoldingsChannel.com獲取Health Catalyst,Inc.(納斯達克代碼:HCAT-GET Rating)的最新13F備案文件和內幕交易信息。
Receive News & Ratings for Health Catalyst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Catalyst and related companies with MarketBeat.com's FREE daily email newsletter.
接受每日健康催化劑的新聞和評級-在下面輸入您的電子郵件地址,以通過MarketBeat.com的免費每日電子郵件時事通訊接收對Health Catalyst和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。